Goldman Sachs Group Inc. lessened its stake in shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 20.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 97,180 shares of the company’s stock after selling 24,314 shares during the quarter. Goldman Sachs Group Inc. owned about 0.15% of Aralez Pharmaceuticals worth $131,000 at the end of the most recent reporting period.

Separately, GSA Capital Partners LLP increased its stake in shares of Aralez Pharmaceuticals by 88.5% during the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock valued at $731,000 after acquiring an additional 254,400 shares during the period. Institutional investors and hedge funds own 23.54% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aralez Pharmaceuticals Inc. (ARLZ) Shares Sold by Goldman Sachs Group Inc.” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/aralez-pharmaceuticals-inc-arlz-shares-sold-by-goldman-sachs-group-inc/1721132.html.

Separately, Chardan Capital lowered their price objective on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 10th.

Aralez Pharmaceuticals Inc. (NASDAQ ARLZ) opened at $1.65 on Thursday. Aralez Pharmaceuticals Inc. has a 12 month low of $0.95 and a 12 month high of $5.31. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.02. The business had revenue of $24.30 million for the quarter, compared to analyst estimates of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The business’s revenue for the quarter was up 78.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.32) earnings per share. equities research analysts expect that Aralez Pharmaceuticals Inc. will post -1.54 earnings per share for the current year.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.